Page 162 - 2019_09-HaematologicaMondo-web

J. Lu et al.
27. Malcikova J, Stano-Kozubik K, Tichy B, et
al. Detailed analysis of therapy-driven clon- al evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia. 2015; 29(4):877-885.
28. Bulian P, Shanafelt TD, Fegan C, et al. CD49d is the strongest flow cytometry- based predictor of overall survival in chron- ic lymphocytic leukemia. J Clin Oncol. 2014;32(9):897-904.
29. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic fac- tor in B-cell chronic lymphocytic leukemia. Blood. 2001;98(1):181-186.
30. Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lym- phocytic leukemia. Cancer. 1987; 60(11):2712-2716.
31. Viñolas N, Reverter JC, Urbano-Ispizua A, Montserrat E, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukemia: an update of its prognostic signif- icance. Blood Cells. 1987;12(2):457-470.
32. Cruse JM, Lewis RE, Webb RN, Sanders CM, Suggs JL. Zap-70 and CD38 as predic- tors of IgVH mutation in CLL. Exp Mol Pathol. 2007;83(3):459-461.
33. Cazzola M, Rossi M, Malcovati L, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Biologic and clinical sig- nificance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood. 2013;121(2):260-269.
34. Benevolenskaya EV, Frolov MV. Emerging links between E2F control and mitochondr- ial function. Cancer Res. 2015;75(4):619- 623.
35. Morita M, Gravel S-P, Chénard V, et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab. 2013; 18(5):698-711.
36. Tornatore L, Thotakura AK, Bennett J, Moretti M, Franzoso G. The nuclear factor kappa B signaling pathway: integrating
metabolism with inflammation. Trends
Cell Biol. 2012;22(11):557-566.
37. Saba NS, Liu D, Herman SEM, et al.
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. Blood. 2016;128(1):82–92.
38. Weil R, Israël A. T-cell-receptor- and B-cell- receptor-mediated activation of NF-κB in lymphocytes. Curr Opin Immunol. 2004; 16(3):374-381.
39. Jitschin R, Braun M, Qorraj M, et al. Stromal cell-mediated glycolytic switch in CLL cells involves Notch-c-Myc signaling. Blood. 2015;125(22):3432-3436.
40. Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F. Role of fluorine-18 fluoro- deoxyglucose positron emission tomogra- phy scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer. 2006;107(1):175–183.
41. Morrish F, Hockenbery D. MYC and mito- chondrial biogenesis. Cold Spring Harb Perspect Med. 2014;4(5):a014225–a014225.
1840
haematologica | 2019; 104(9)